One of the biggest differentiators at Integra Connect is our people! Get to know the talented individuals who provide outstanding support to our business day in and day out. As part of our #peoplebehindtheproduct program, meet one of our Senior Technical Managers, Krishanth Rajkumar.
Integra Connect
IT Services and IT Consulting
West Palm Beach, Florida 247,973 followers
About us
Integra Connect is driven to make specialty care practices clinically and financially successful through value-based, precision medicine. While other companies may focus on one of these areas, Integra Connect’s combined focus means providers, payers, and life sciences companies can harness value-based, precision medicine principles to improve their decision-making and make a difference in patients’ lives.
- Website
-
http://www.integraconnect.com
External link for Integra Connect
- Industry
- IT Services and IT Consulting
- Company size
- 1,001-5,000 employees
- Headquarters
- West Palm Beach, Florida
- Type
- Privately Held
- Specialties
- Healthcare, Technology, Population Health, Precision Medicine, Oncology, Cancer Care, and Payer
Locations
-
Primary
Get directions
501 S Flagler Dr
West Palm Beach, Florida 33401, US
Employees at Integra Connect
Updates
-
One of the biggest differentiators at Integra Connect is our people! Get to know the talented individuals who provide outstanding support to our business day in and day out. As part of our #peoplebehindtheproduct program, meet one of our Lead Software Engineers, Tim Shaffer.
-
-
Come check out one of Integra Connect PrecisionQ’s poster presentations at ESMO at the Messe Berlin in Berlin, Germany today, Monday, October 20, 2025, from 12:00-12:45 CEST. This poster presents: Real-World Study on ESR1 Positivity Rate in Correlation to Length of Exposure on Endocrine Therapy +/- CDK4/6i The findings on this study demonstrate that patient duration of exposure to endocrine therapy increases the likelihood of acquiring an ESR1 mutation. Poster 521P / Abstract 2710 Link to Abstract: https://lnkd.in/eJsutDiR Authors: Michael Gart | Erin Alwon | Ashley Lamb | Kristen Henn | Prateesh Varughese PharmD MBA | Brandon Wang | Lisa M. | Robert Geller | Jeffrey Scott
-
-
Come check out one of Integra Connect PrecisionQ’s poster presentations at ESMO at the Messe Berlin in Berlin, Germany today, Monday, October 20, 2025, from 12:00-12:45 CEST. This poster presents: Real-World study on rates of positivity for ESR1, PIK3CA, PTEN, and ATK1 among ER+/HER2- metastatic breast cancer patients The real-world analysis shows that nearly 50% of patients harbor either PTEN, AKT1, or PIK3CA mutations with nearly a third of those patients also harboring an ESR1 mutation. The results underscore the importance for healthcare providers to implement routine Next Generation Sequencing testing at disease progression to identify relevant biomarkers to direct guideline concordant care. Poster 527P / Abstract 3856 Link to Abstract: https://lnkd.in/eNjRE-Jf Authors: Michael Gart | Erin Alwon | Ashley Lamb | Kristen Henn | Prateesh Varughese PharmD MBA | Brandon Wang | Lisa M. | Robert Geller | Jeffrey Scott
-
-
Come check out one of Integra Connect PrecisionQ’s poster presentations at ESMO at the Messe Berlin in Berlin, Germany today, Monday, October 20, 2025, from 12:00-12:45 CEST. This poster presents: Real-World Study on the Significance of Next Generation Sequencing Testing for ESR1 in ER+/HER2- Metastatic Breast Cancer Patients After Endocrine Therapy Progression The real-world study shows the importance of testing for ESR1 mutations at the time of progression to best identify the presence of ESR1 mutations as pts who were tested closest to their time of progression had the highest rate of ESR1 mutations. Poster 506P / Abstract 3877 Link to Abstract: https://lnkd.in/e48gCCaM Authors: Michael Gart | Erin Alwon | Ashley Lamb | Kristen Henn | Prateesh Varughese PharmD MBA | Brandon Wang | Lisa M. | Robert Geller | Jeffrey Scott
-
-
Check out one of Integra Connect PrecisionQ’s poster presentations from ESMO. This poster presents: Quality initiative for patients with HR+/HER2-, node-positive, early breast cancer at a high risk of recurrence Practices who participated in the HR+/HER2- early stage breast cancer QI had higher guideline concordance of using CDK4/6i + ET among pts who received adjuvant treatment that were at a high risk of recurrence. The QI demonstrates the benefit of implementing quality improvement programs to improve guideline adherence. Poster 440eP / Abstract 3899 Link to Abstract: https://lnkd.in/eyPBTtJz Authors: Michael Gart | Pinyao Anna Rui | Teena Sura | Ashley Lamb | Lindsay Aton | Prateesh Varughese PharmD MBA | Brandon Wang | Lisa M. | Jeffrey Scott | Robert Geller
-
-
One of the biggest differentiators at Integra Connect is our people! Get to know the talented individuals who provide outstanding support to our business day in and day out. As part of our #peoplebehindtheproduct program, meet one of our Technical Managers, Venkataramana Radhakrishnan.
-
-
One of the biggest differentiators at Integra Connect is our people! Get to know the talented individuals who provide outstanding support to our business day in and day out. As part of our #peoplebehindtheproduct program, meet our Director of Data Operations, Aaron Goddard.
-
-
One of the biggest differentiators at Integra Connect is our people! Get to know the talented individuals who provide outstanding support to our business day in and day out. As part of our #peoplebehindtheproduct program, meet one of our Product Managers, Jacob Ley, PMP, MPH.
-